Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 2
1957 1
1959 5
1960 2
1962 3
1964 2
1965 2
1966 3
1967 5
1968 6
1969 8
1970 10
1971 5
1972 9
1973 11
1974 5
1975 8
1976 10
1977 13
1978 10
1979 10
1980 11
1981 6
1982 14
1983 10
1984 12
1985 12
1986 17
1987 21
1988 24
1989 24
1990 26
1991 24
1992 31
1993 42
1994 54
1995 48
1996 71
1997 78
1998 77
1999 104
2000 125
2001 124
2002 119
2003 188
2004 250
2005 266
2006 275
2007 347
2008 330
2009 380
2010 417
2011 513
2012 549
2013 557
2014 534
2015 583
2016 558
2017 561
2018 507
2019 529
2020 594
2021 605
2022 489
2023 467
2024 202

Text availability

Article attribute

Article type

Publication date

Search Results

9,764 results

Results by year

Filters applied: . Clear all
Page 1
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Ramalingam SS, et al. Among authors: lee kh. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21. N Engl J Med. 2020. PMID: 31751012 Free article. Clinical Trial.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. Among authors: lee kh. N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280658 Free article. Clinical Trial.
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses.
Wang M, Rousseau B, Qiu K, Huang G, Zhang Y, Su H, Le Bihan-Benjamin C, Khati I, Artz O, Foote MB, Cheng YY, Lee KH, Miao MZ, Sun Y, Bousquet PJ, Hilmi M, Dumas E, Hamy AS, Reyal F, Lin L, Armistead PM, Song W, Vargason A, Arthur JC, Liu Y, Guo J, Zhou X, Nguyen J, He Y, Ting JP, Anselmo AC, Huang L. Wang M, et al. Among authors: lee kh. Nat Biotechnol. 2023 Sep 25. doi: 10.1038/s41587-023-01957-8. Online ahead of print. Nat Biotechnol. 2023. PMID: 37749267
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. Among authors: lee kh. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. Among authors: lee kh. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Ssangcheon, Life of Lee Young-Choon (1903-1980).
Lee KH, Lee JM, Yoon SJ, Lee CS. Lee KH, et al. Yonsei Med J. 2024 Apr;65(4):189-193. doi: 10.3349/ymj.2023.0445. Yonsei Med J. 2024. PMID: 38515355 Free PMC article. No abstract available.
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Bang YJ, et al. Among authors: lee kh. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7. Lancet. 2012. PMID: 22226517 Clinical Trial.
Endometriosis-Related Chronic Pelvic Pain.
Song SY, Jung YW, Shin W, Park M, Lee GW, Jeong S, An S, Kim K, Ko YB, Lee KH, Kang BH, Lee M, Yoo HJ. Song SY, et al. Among authors: lee kh. Biomedicines. 2023 Oct 23;11(10):2868. doi: 10.3390/biomedicines11102868. Biomedicines. 2023. PMID: 37893241 Free PMC article. Review.
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
Cho BC, Kim DW, Spira AI, Gomez JE, Haura EB, Kim SW, Sanborn RE, Cho EK, Lee KH, Minchom A, Lee JS, Han JY, Nagasaka M, Sabari JK, Ou SI, Lorenzini P, Bauml JM, Curtin JC, Roshak A, Gao G, Xie J, Thayu M, Knoblauch RE, Park K. Cho BC, et al. Among authors: lee kh. Nat Med. 2023 Oct;29(10):2577-2585. doi: 10.1038/s41591-023-02554-7. Epub 2023 Sep 14. Nat Med. 2023. PMID: 37710001 Free PMC article. Clinical Trial.
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Cho BC, et al. Among authors: lee kh. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. doi: 10.1200/JCO.23.00515. Epub 2023 Jun 28. J Clin Oncol. 2023. PMID: 37379502 Clinical Trial.
9,764 results